Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities
Yaozong Chen, Lulu Sun, Irfan Ullah, et al.
Science Advances (2022) Vol. 8, Iss. 28
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS‐CoV ‐2
Lianghui Zhang, Krishna K. Narayanan, Laura Cooper, et al.
EMBO Molecular Medicine (2022) Vol. 14, Iss. 11
Open Access | Times Cited: 45
Next-generation treatments: Immunotherapy and advanced therapies for COVID-19
Jenny Andrea Arévalo-Romero, Sandra M. Chingaté-López, Bernardo Camacho, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e26423-e26423
Open Access | Times Cited: 8
Engineering ACE2 decoy receptors to combat viral escapability
Takao Arimori, Nariko Ikemura, Toru Okamoto, et al.
Trends in Pharmacological Sciences (2022) Vol. 43, Iss. 10, pp. 838-851
Open Access | Times Cited: 30
The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice
Irfan Ullah, Guillaume Beaudoin-Bussières, Kelly Symmes, et al.
Cell Reports Medicine (2022) Vol. 4, Iss. 1, pp. 100893-100893
Open Access | Times Cited: 29
S Protein, ACE2 and Host Cell Proteases in SARS-CoV-2 Cell Entry and Infectivity; Is Soluble ACE2 a Two Blade Sword? A Narrative Review
Reza Nejat, Maziar Fayaz Torshizi, David J. Najafi
Vaccines (2023) Vol. 11, Iss. 2, pp. 204-204
Open Access | Times Cited: 15
Plants as Biofactories for Therapeutic Proteins and Antiviral Compounds to Combat COVID-19
Corbin England, Jonathan TrejoMartinez, Paula PerezSanchez, et al.
Life (2023) Vol. 13, Iss. 3, pp. 617-617
Open Access | Times Cited: 15
Protective non-neutralizing SARS-CoV-2 monoclonal antibodies
Arman Izadi, Pontus Nordenfelt
Trends in Immunology (2024) Vol. 45, Iss. 8, pp. 609-624
Open Access | Times Cited: 6
Deciphering Fc-effector functions against SARS-CoV-2
Guillaume Beaudoin-Bussières, Andrés Finzi
Trends in Microbiology (2024) Vol. 32, Iss. 8, pp. 756-768
Closed Access | Times Cited: 5
An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2
Lianghui Zhang, Krishna K. Narayanan, Laura Cooper, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 22
Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides
George N. Llewellyn, Hsu-Yu Chen, Geoffrey L. Rogers, et al.
Journal of Virology (2023) Vol. 97, Iss. 8
Open Access | Times Cited: 12
Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivo
James A. Torchia, Alexander H. Tavares, Laura Stentoft Carstensen, et al.
Science Advances (2022) Vol. 8, Iss. 49
Open Access | Times Cited: 19
A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo
Brandon Havranek, Graeme Walker Lindsey, Yusuke Higuchi, et al.
Communications Biology (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 9
Intranasal soluble ACE2 improves survival and prevents brain SARS-CoV-2 infection
Luise Hassler, Jan Wysocki, Jared T. Ahrendsen, et al.
Life Science Alliance (2023) Vol. 6, Iss. 7, pp. e202301969-e202301969
Open Access | Times Cited: 8
Multimeric ACE2-IgM fusions as broadly active antivirals that potently neutralize SARS-CoV-2 variants
Hristo L. Svilenov, Romina Bester, Julia Sacherl, et al.
Communications Biology (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 13
Counter-regulatory renin-angiotensin system in hypertension: Review and update in the era of COVID-19 pandemic
Hongyin Chen, Jiangyun Peng, Tengyao Wang, et al.
Biochemical Pharmacology (2022) Vol. 208, pp. 115370-115370
Open Access | Times Cited: 13
Specific Activation of T Cells by an ACE2-Based CAR-Like Receptor upon Recognition of SARS-CoV-2 Spike Protein
Pablo Gonzalez-Garcia, Juan Pedro Muñoz-Miranda, Ricardo Fernández-Cisnal, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 8, pp. 7641-7641
Open Access | Times Cited: 6
Immunogenicity and Pre-Clinical Efficacy of an OMV-Based SARS-CoV-2 Vaccine
Alberto Grandi, Michele Tomasi, Irfan Ullah, et al.
Vaccines (2023) Vol. 11, Iss. 10, pp. 1546-1546
Open Access | Times Cited: 6
Multivalent ACE2 engineering—A promising pathway for advanced coronavirus nanomedicine development
Eugene M. Obeng, Isaac Fianu, Michael K. Danquah
Nano Today (2022) Vol. 46, pp. 101580-101580
Open Access | Times Cited: 10
Host range and structural analysis of bat‐origin RshSTT182/200 coronavirus binding to human ACE2 and its animal orthologs
Yu Hu, Kefang Liu, Pu Han, et al.
The EMBO Journal (2022) Vol. 42, Iss. 4
Open Access | Times Cited: 10
Extrinsic stabilization of antiviral ACE2-Fc fusion proteins targeting SARS-CoV-2
Hristo L. Svilenov, Florent Delhommel, Till Siebenmorgen, et al.
Communications Biology (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 5
Broadly Effective ACE2 Decoy Proteins Protect Mice from Lethal SARS-CoV-2 Infection
Mengjia Lu, Weitong Yao, Yujun Li, et al.
Microbiology Spectrum (2023) Vol. 11, Iss. 4
Open Access | Times Cited: 5
Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
Bruce D. Wines, Liriye Kurtovic, Halina M. Trist, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 9
Anti-SARS-CoV-2 immunoadhesin remains effective against Omicron and other emerging variants of concern
Hadas Cohen‐Dvashi, Jonathan J. Weinstein, Michael Katz, et al.
iScience (2022) Vol. 25, Iss. 10, pp. 105193-105193
Open Access | Times Cited: 9
Stellabody: A novel hexamer‐promoting mutation for improved IgG potency
Clarissa A. Whitehead, Bruce D. Wines, Anna M. Davies, et al.
Immunological Reviews (2024)
Open Access | Times Cited: 1
Computational pipeline provides mechanistic understanding of Omicron variant of concern neutralizing engineered ACE2 receptor traps
Soumya G. Remesh, Gregory E. Merz, Axel F. Brilot, et al.
Structure (2023) Vol. 31, Iss. 3, pp. 253-264.e6
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top